Erythropoietin (epo) Or Derivative Patents (Class 514/7.7)
-
Patent number: 8796207Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.Type: GrantFiled: October 5, 2012Date of Patent: August 5, 2014Assignee: Lipoxen Technologies LimitedInventors: Gregory Gregoriadis, Sanjay Jain, Peter Laing, Norbert Oskar Rumpf
-
Patent number: 8796206Abstract: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.Type: GrantFiled: November 13, 2008Date of Patent: August 5, 2014Assignee: Amgen Inc.Inventors: Christopher James Sloey, Jason Ko, Tiansheng Li
-
Publication number: 20140200180Abstract: Methods for producing proteins and glycoproteins in Pichia pastoris that lack detectable cross binding activity to antibodies made against host cell antigens are described. In particular, methods are described wherein recombinant Pichia pastoris strains that do not display a ?-mannosyltransferase 2 activity with respect to an N-glycan or O-glycan and do not display at least one activity selected from a ?-mannosyltransferase 1, 3, and 4 activity to produce recombinant proteins and glycoproteins. These recombinant Pichia pastoris strains can produce proteins and glycoproteins that lack detectable ?-mannosidase resistant ?-mannose residues thereon and thus, lack cross binding activity to antibodies against host cell antigens. Further described are methods for producing bi-sialylated human erythropoietin in Pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens.Type: ApplicationFiled: January 15, 2014Publication date: July 17, 2014Applicant: Merck Sharp & Dohme CorpInventors: Piotri Bobrowicz, Sujatha Gomathinayagam, Stephen Hamilton, Huijuan Li, Natarajan Setheraman, Terrance A. Stadheim, Stephan Wildt
-
Publication number: 20140200181Abstract: A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, and employing the patient parameters and an initially selected EPO administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen.Type: ApplicationFiled: September 7, 2012Publication date: July 17, 2014Inventors: Doris Helene Fuertinger, Franz Kappel, Peter Kotanko, Nathan W. Levin, Stephan Thijssen
-
Publication number: 20140193360Abstract: The present invention relates to an adhesive hydrogel composition containing catechol group-coupled chitosan and Pluronic comprising a thiol group coupled to the end thereof, and more specifically, to an adhesive composition which is safe in vivo and in vitro, is temperature sensitive, and has an excellent hemostatic effect and thus can be used as a bioadhesive, and a medical adhesive, an adhesion barrier and a surface adsorption inhibitor comprising the same.Type: ApplicationFiled: November 21, 2011Publication date: July 10, 2014Applicant: Innotherapy Inc.Inventors: Haeshin Lee, Moon Sue Lee, Ji Hyun Ryu
-
Publication number: 20140193393Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.Type: ApplicationFiled: January 7, 2014Publication date: July 10, 2014Applicant: MIDWESTERN UNIVERSITYInventor: ANIL GULATI
-
Patent number: 8765924Abstract: This invention relates to novel protein conjugates, in particular, to novel pegylated proteins, and their methods of making and use. One aspect of the present invention relates to pegylated-erythropoietin having greater clinical efficacy and stability during shipment and storage than current erythropoietin formulations.Type: GrantFiled: July 16, 2007Date of Patent: July 1, 2014Assignee: Prolong Pharmaceuticals, Inc.Inventors: Abraham Abuchowski, Lihsyng Stanford Lee
-
Publication number: 20140154205Abstract: A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.Type: ApplicationFiled: February 10, 2014Publication date: June 5, 2014Applicant: Remedor Biomed Ltd.Inventor: Saher HAMED
-
Patent number: 8734527Abstract: Provided are therapeutic implants comprising renal tissue encapsulated within a polymer bead. Also disclosed are methods for treating a disease state in a subject comprising implanting within said subject a therapeutic implant comprising renal tissue encapsulated within a polymer bead. Also provided are methods for making a therapeutic implant comprising: providing renal tissue; mixing the renal tissue with a solution comprising a polymer, thereby forming a tissue-polymer suspension; extruding the tissue-polymer suspension into an bead-forming solution, thereby forming a therapeutic implant comprising beads of said polymer within which the renal tissue is encapsulated.Type: GrantFiled: December 17, 2008Date of Patent: May 27, 2014Assignee: Advanced Technologies and Regenerative Medicine, LLCInventors: Charito S. Buensuceso, David C. Colter, Brian C. Kramer, Agnieszka Seyda
-
Patent number: 8729030Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: GrantFiled: November 12, 2010Date of Patent: May 20, 2014Assignee: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Palani Balu, Genet Zemede
-
Publication number: 20140120100Abstract: The inventors have discovered that both soluble erythropoietin-binding protein and antibodies against the erythropoietin-binding protein, when they are administered to a mammal along with erythropoietin (Epo), prevent or reduce the blood pressure increase normally caused by erythropoietin, while not affecting the hematocrit increase that is the purpose of Epo treatment. The invention provides a method of treating anemia in a mammal involving: administering erythropoietin (Epo) to the mammal; and administering to the mammal an agent selected from a soluble Epo-binding protein (Epo-bp), a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor, and a combination thereof. The invention also provides a method of reducing hypertension in a mammal receiving Epo, and pharmaceutical compositions containing a soluble Epo-bp and/or a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor.Type: ApplicationFiled: September 30, 2013Publication date: May 1, 2014Inventors: Jong Y. Lee, John S. Lee, Mary S. Lee
-
Publication number: 20140105856Abstract: System and methods for isolation of collagen and other fibrous tissue from adipose tissue are described herein. The method of the present invention isolates the collagen from adipose tissue by sonication. The tissue to be sonicated is placed in a container or a flow cell transparent to ultrasound waves. After sonication the sonicated material is filtered out through the bottom of the flow cell and the sonicated collagen is trapped in the filter, which may be taken for further processing. The isolated collagen can then be combined with a suitable carrier for re-injection to correct various tissue defects such as wrinkles, to form a carrier for the stem cells, a filler, and matrix for new collagen production by injecting into the desired area of the host.Type: ApplicationFiled: June 22, 2012Publication date: April 17, 2014Inventor: Stephen Schendel
-
Patent number: 8691767Abstract: Method for treatment and/or prophylaxis of schizophrenia and related psychoses of a human being, erythropoietin being administered to the human being.Type: GrantFiled: January 31, 2012Date of Patent: April 8, 2014Inventor: Hannelore Ehrenreich
-
Publication number: 20140072531Abstract: A method for preparing polymer microparticles with a reduced initial burst, and the polymer microparticles prepared thereby, the method including: contacting polymer microparticles with an alcohol aqueous solution, the polymer microparticles prepared thereby, and use for drug delivery of the polymer microparticles.Type: ApplicationFiled: November 20, 2013Publication date: March 13, 2014Applicant: SK CHEMICALS CO., LTD.Inventors: Hong Kee KIM, Kyu Ho Lee, Joon-Gyo OH, Bong-Yong Lee
-
Patent number: 8664194Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.Type: GrantFiled: May 21, 2013Date of Patent: March 4, 2014Assignee: Moderna Therapeutics, Inc.Inventors: Antonin de Fougerolles, Kristy M. Wood, Sayda M. Elbashir, Jason P. Schrum
-
Publication number: 20140050693Abstract: Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which consist essentially of Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described are related nucleic acids, vectors and cells encoding such amino acids; compositions of biologically active proteins fused to a random coil domain, and methods of making and using the compounds and compositions of the invention.Type: ApplicationFiled: August 9, 2013Publication date: February 20, 2014Applicant: TECHNISCHE UNIVERSITAT MUNCHENInventors: Ame Skerra, Ina Theobald, Martin Schlapschy
-
Patent number: 8653028Abstract: The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.Type: GrantFiled: May 1, 2006Date of Patent: February 18, 2014Inventors: Rui Rong Yuan, Wei Ping Li, Yasuhiro Maeda, Peter Dowling
-
Publication number: 20140045748Abstract: The present invention relates to a composition comprising erythropoietin (EPO) as an active ingredient for aiding surgical procedures for treating ischemic vascular diseases. The present invention also relates to a method for treating ischemic vascular diseases using said composition. The composition for aiding surgical procedures according to the present invention may improve the success rate of a variety of surgical procedures including multiple cutting operations performed on an adult patient suffering from a variety of ischemic vascular diseases including moyamoya disease, and can be widely used in the treatment of a variety of ischemic vascular diseases.Type: ApplicationFiled: April 26, 2012Publication date: February 13, 2014Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventor: Ji Man Hong
-
Patent number: 8642545Abstract: What is provided is EPO mimetic peptide derivatives defined as formula (I) and their pharmaceutical salts, the preparation thereof, wherein R1, R2, R3, R4, R5, n1, n2 are defined as described in description. A composition comprising of an EPO mimetic peptide derivative defined as formula (I) and its pharmaceutical salt. The uses of the derivatives and their pharmaceutical salts, as well as the uses of the compositions described above in treatment of diseases characterized by a deficiency of EPO or a low or defective red blood cell population.Type: GrantFiled: November 24, 2008Date of Patent: February 4, 2014Assignee: Jiangsu Hansoh Pharmaceutical Co., LtdInventors: Aifeng Lü, Changan Sun, Tao Jiang, Wentao Wu, Yali Wang
-
Patent number: 8633157Abstract: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.Type: GrantFiled: June 2, 2005Date of Patent: January 21, 2014Assignee: Novo Nordisk A/SInventors: Shawn DeFrees, Robert J. Bayer, David A. Zopf
-
Publication number: 20140011740Abstract: Modified animal erythropoietin polypeptides and uses thereof are provided.Type: ApplicationFiled: September 20, 2013Publication date: January 9, 2014Applicants: Eli Lilly Company, Ambrx, Inc.Inventors: Feng TIAN, Anna-Maria A. HAYS PUTNAM, Frank SONG, Stephanie CHU, Joseph SHEFFER, Richard S. BARNETT, Marc SILADI, Kyle ATKINSON, Darin LEE, Peter C. CANNING
-
Publication number: 20140005109Abstract: Disclosed are isolated mutant erythropoietin (EPO) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant EPO peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substitution at position 76. This substitution inhibits erythropoietic activity while retaining their neuroprotection. Also disclosed are methods of treating or inhibiting neuronal degeneration, reducing or inhibiting one or more symptoms associated with neuronal degeneration and/or glaucoma in a subject. The methods include administering a therapeutically effective amount of a isolated mutant erythropoietin EPO polypeptide, an expression vector encoding such a mutant erythropoietin EPO polypeptide, a viral particle including an expression vector, or a composition, thereby treating or inhibiting neuronal degeneration in the subject.Type: ApplicationFiled: January 13, 2012Publication date: January 2, 2014Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Tonia S. Rex, Timothy A. Sullivan
-
Patent number: 8618266Abstract: The present invention relates to hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide) comprising one or more HAS molecules, wherein each HAS is conjugated to the polypeptide via a carbohydrate moiety or a thioether as well as to methods for the production thereof. In a preferred embodiment, the polypeptide is erythropoietin (EPO).Type: GrantFiled: March 11, 2005Date of Patent: December 31, 2013Assignee: Fresenius Kabi Deutschland GmbHInventors: Harald S. Conradt, Eckart Grabenhorst, Manfred Nimtz, Norbert Zander, Ronald Frank, Wolfram Eichner
-
Publication number: 20130344027Abstract: Multifunctional polymers are disclosed having a smart segment and a biodegradable segment. Advantageously, the biodegradable segment includes a hydrophilic segment and a hydrophobic segment. Embodiments include combining the multifunctional polymeric material with a biologically active substance in an aqueous loading environment and administering the composition as a drug delivery vehicle to a human subject.Type: ApplicationFiled: August 27, 2013Publication date: December 26, 2013Applicant: University of Tennessee Research FoundationInventors: Tao Lu Lowe, Young Shin Kim, Xiao Huang
-
Publication number: 20130323199Abstract: A collagen material is characterized in being constituted of collagen gel fragments. Furthermore, the collagen gel fragments may have an orientation. A method for producing a collagen material is characterized in comprising a step for preparing collagen gel fragments, a step for arranging the collagen gel fragments in a desired shape, and a step for drying the collagen gel fragments arranged in the desired shape. Moreover, in one embodiment of the method for producing a collagen material a step may include imparting an orientation to the collagen gel fragments.Type: ApplicationFiled: February 20, 2012Publication date: December 5, 2013Applicant: Atree, Inc.Inventors: Taro Saku, Yoshihiro Isobe, Takaoki Isobe
-
Patent number: 8586531Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: June 11, 2012Date of Patent: November 19, 2013Assignees: Genexine, Inc., Postech Academy-Industry Foundation of Phohang University of Science and Technology (Postech)Inventors: Sehwan Yang, Young Chul Sung
-
Publication number: 20130295156Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.Type: ApplicationFiled: April 23, 2013Publication date: November 7, 2013Inventor: OrbusNeich Medical, Inc.
-
Patent number: 8569233Abstract: Modified animal erythropoietin polypeptides and uses thereof are provide.Type: GrantFiled: July 24, 2012Date of Patent: October 29, 2013Assignees: Eli Lilly and Company, AMBRX, Inc.Inventors: Feng Tian, Anna-Maria A. Hays Putnam, Frank Song, Stephanie Chu, Joseph Sheffer, Richard S. Barnett, Marc Siladi, Kyle Atkinson, Darin Lee, Peter C. Canning
-
Publication number: 20130274188Abstract: The present invention relates to a macromolecule for delivering protein, polypeptide or peptide drugs and to a production method for the same, as well as to a slow release composition for protein, polypeptide or peptide drugs comprising the same, and more specifically relates to a polylactic acid derivative compound of Chemical formula 1 of which the numerical average molecular weight is no more than 7000 daltons and to a production method for the same, as well as to a slow release composition for protein, polypeptide or peptide drugs using the same and to a production method for the same.Type: ApplicationFiled: December 28, 2010Publication date: October 17, 2013Inventors: Yil Woong Yi, Min Hyo Seo, Bong Oh Kim, In Ja Choi, Hye Jeong Yoon, Se Yoon Kim, Sang Jun Lee, Joong Woong Cho
-
Patent number: 8546329Abstract: The present invention relates to an erythropoietin-containing solution preparation containing a poloxamer and having a pH of 6.5 to 7.5. The present invention also relates to a method for quantifying a protein in a trace amount, the method including the following steps: binding a protein sample to a high-intensity fluorescent dye; separating a desired analyte from the obtained sample by an appropriate separation means; and quantifying the desired analyte and converting the amount of the analyte into the amount of the protein.Type: GrantFiled: March 22, 2007Date of Patent: October 1, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hidefumi Mizushima, Takayuki Yoshimori
-
Publication number: 20130243866Abstract: A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in ?-sheet structure dominant silk microsphere structures having about 2 ?m in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments.Type: ApplicationFiled: May 7, 2013Publication date: September 19, 2013Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. KAPLAN, Xiaoqin WANG
-
Patent number: 8536123Abstract: A method that includes a measurement of hemoglobin or hematocrit with a measurement of hemodynamic parameters to monitor and/or control a modality of treatment of a patient suffering from anemia.Type: GrantFiled: January 9, 2009Date of Patent: September 17, 2013Assignee: Health Onvector Inc.Inventor: Daniel J. Cho
-
Publication number: 20130236432Abstract: The invention relates to an in-vitro and in-vivo method for multiplying and differentiating cells, during which the growth process of the cells is initiated or terminated and structurally directed by the use of growth factors thrombopoietin (TPO) and/or erythropoietin (EPO), and/or growth hormone (GH), particularly human growth hormone (HGH), and/or somatostatin and/or leukemia inhibitory factor (LIF) and/or ciliary neurotropic factor (CNTF). The invention also relates to a biological matrix or supporting structure containing the aforementioned growth factors, and to a method and device for the production thereof and for carrying out the inventive method.Type: ApplicationFiled: April 22, 2013Publication date: September 12, 2013Inventor: Augustinus BADER
-
Publication number: 20130230598Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.Type: ApplicationFiled: February 20, 2013Publication date: September 5, 2013Applicant: LG LIFE SCIENCES, LTD., INC.Inventors: Myung-Jin KIM, Sun-Jin KIM, Oh-Ryong KWON
-
Publication number: 20130230485Abstract: The present invention provides methods for treating a patient undergoing multi-cycle chemotherapy that provides significantly improved platelet counts in the patients, and facilitates retention of dose intensity from cycle to cycle of the chemotherapy.Type: ApplicationFiled: February 28, 2013Publication date: September 5, 2013Inventors: Kathleen E. Rodgers, Gere S. diZerega
-
Patent number: 8518879Abstract: The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising cell culture medium conditioned by cells grown in two-dimensional culture. Also included are methods of using such compositions and kits comprising the skin cream therein.Type: GrantFiled: March 4, 2011Date of Patent: August 27, 2013Inventor: Ahmed H. Al-Qahtani
-
Publication number: 20130203668Abstract: A composition comprising suitable anti-platelet agent/agents and the erythropoiesis stimulating agent for the treatment and improvement of kidney function is described. The combination also provides treatment and improvement in cardiovascular and bleeding related disorders. This composition shows synergistic interaction and significantly reduces the kidney damage caused by administration of erythropoiesis stimulating agents. Moreover the present composition normalizes the platelet reactivity and bleeding time in patients with chronic kidney disease.Type: ApplicationFiled: April 18, 2011Publication date: August 8, 2013Applicant: CADILA HEALTHCARE LIMITEDInventors: Hitesh Madanlal Soni, Mukul R. Jain
-
Publication number: 20130196907Abstract: Methods are provided for promoting the production of erythropoietin and the production of erythrocytes and hematopoietic stem and progenitor cells. These methods find us in the treatment of subjects with conditions in which erythrocyte cell numbers are reduced, for example, anemia, chronic kidney disease, and following chemotherapy treatment.Type: ApplicationFiled: April 15, 2011Publication date: August 1, 2013Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventor: The Board of Trustees of the Leland Standford Junior University
-
Publication number: 20130177532Abstract: The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.Type: ApplicationFiled: August 20, 2012Publication date: July 11, 2013Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20130178417Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.Type: ApplicationFiled: August 30, 2012Publication date: July 11, 2013Inventors: Michael P. AREND, Lee A. FLIPPIN, Volkmar GUENZLER-PUKALL, Wen-Bin HO, Eric D. TURTLE, Xiaohui DU
-
Patent number: 8470369Abstract: Bone paste compositions are described, which promote bone healing and remodeling by stimulating bone marrow elements using a combination of hemopoietic agents, angiogenic agents and a bone molecular signaling material.Type: GrantFiled: March 10, 2009Date of Patent: June 25, 2013Assignee: Marfly 2, L.PInventor: J. Alexander Marchosky
-
Publication number: 20130143806Abstract: Certain embodiments of the present invention relate to methods for detecting kidney disease, in particular early stage kidney disease.Type: ApplicationFiled: April 21, 2011Publication date: June 6, 2013Applicant: Regents of the University of MinnesotaInventor: Gary Nelsestuen
-
Publication number: 20130130979Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: October 18, 2012Publication date: May 23, 2013Applicant: AFFYMAX, INC.Inventor: AFFYMAX, INC.
-
Publication number: 20130116176Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.Type: ApplicationFiled: October 5, 2012Publication date: May 9, 2013Applicant: Lipoxen Technologies LimitedInventor: Lipoxen Technologies Limited
-
Patent number: 8435949Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.Type: GrantFiled: June 11, 2012Date of Patent: May 7, 2013Assignee: Stem Cell Therapeutics Corp.Inventors: Samuel Weiss, Emeka Enwere, Linda Andersen, Christopher Gregg
-
Publication number: 20130102530Abstract: Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.Type: ApplicationFiled: June 13, 2012Publication date: April 25, 2013Applicant: The Kenneth S. Warren Institute, Inc.Inventors: Michael Brines, Anthony Cerami, Carla Cerami
-
Publication number: 20130095060Abstract: The present invention relates to a pharmaceutical composition for promoting arteriogenesis, and preparation method and applications of the same, wherein said pharmaceutical composition comprises an effective amount of a drug, and a peptide hydrogel, and it forms a microenvironment for autologous cell recruitment and tissue regeneration.Type: ApplicationFiled: April 10, 2012Publication date: April 18, 2013Applicant: National Cheng Kung UniversityInventors: PATRICK C.H. HSIEH, YI-DONG LIN
-
Publication number: 20130095062Abstract: The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against those authentic recombinant proteins.Type: ApplicationFiled: July 18, 2012Publication date: April 18, 2013Inventors: Ridong Chen, Soon Seog Jeong, Hui Feng
-
Publication number: 20130089513Abstract: Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 2, 2012Publication date: April 11, 2013Applicant: Medexgen Co., Ltd.Inventors: Yong-Hoon Chung, Hak-sup Lee, Ki-Wan Yi, Youn-Hwa Heo, Jae-Youn Kim
-
Publication number: 20130078213Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: ApplicationFiled: August 24, 2012Publication date: March 28, 2013Inventors: Kevin J. Duffy, Connie Erickson-Miller, Daniel F. Eppley, Julian Jenkins, Juan I. Luengo, Nannan Liu, Alan T. Price, Antony N. Shaw, Sophie Visonneau, Kenneth Wiggall